Best Case
15%TEMPO and ACCESS become a repeatable path for safe digital devices to reach Medicare patients while tying payment to verified outcomes.
Forecast dossier
Digital health reimbursement will increasingly require outcome data during real-world deployment
FDA selected the first participant for its TEMPO digital health devices pilot, involving Dexcom and a glucose health program intended for use with the CMS ACCESS model. ACCESS began in July 2026 as a 10-year Medicare model using outcome-aligned payments for technology-supported chronic care. The likely durable change is a tighter bridge between device oversight, Medicare payment, and continuous real-world evidence collection.
Verdict: Qualifying forecast. The policy mechanism is concrete and newly activated, but broad impact depends on patient uptake, outcome measurement integrity, and whether CMS expands beyond early participants.
Date
Jul 22, 2026
Reliability
76
Harm potential
Medium
Scenario odds
Baseline
50%The model expands gradually in biomarker-heavy chronic care, especially diabetes and cardio-kidney-metabolic management.
Adverse Case
25%Evidence collection is noisy, patient engagement fades, and CMS limits expansion because savings or outcomes are unclear.
Wildcard
10%A major safety, privacy, or algorithmic-bias incident forces FDA and CMS to slow the pathway and impose stricter monitoring.
Timeline projections
1-Year
Pilot proof points
Developments: FDA selects more participants and CMS begins collecting early performance data from ACCESS organizations.
Risks: Low enrollment or confused clinician referral pathways limit early signal quality.
Outlook: The first year tests workflow feasibility more than clinical superiority.
2-Year
Outcome reporting pressure
Developments: Participants begin competing on risk-adjusted outcomes and patient acquisition.
Risks: Marketing may overstate early improvements before robust comparisons exist.
Outlook: Evidence discipline becomes a differentiator for digital health companies.
3-Year
Payment design diffusion
Developments: Commercial plans and Medicare risk-bearing entities copy parts of the outcome-aligned approach.
Risks: Duplicative billing and care fragmentation create compliance disputes.
Outlook: The model spreads if CMS can show credible savings and quality preservation.
5-Year
Regulatory-payment convergence
Developments: Device submissions increasingly include plans for post-market outcome collection and payment-model compatibility.
Risks: Smaller device firms struggle with data infrastructure costs.
Outlook: Digital health moves from app sales toward accountable care infrastructure.
10-Year
Medicare chronic care marketplace
Developments: Patients and clinicians may choose among technology-supported care organizations based on published outcomes.
Risks: Risk selection could leave complex patients underserved.
Outlook: The pathway becomes durable if outcome adjustment is trusted.
20-Year
Continuous evidence care
Developments: Chronic care devices, coaching, medication management, and payment are integrated into continuous feedback systems.
Risks: Privacy, autonomy, and algorithmic oversight become central policy constraints.
Outlook: Digital care becomes normal only where accountability is stronger than convenience claims.
50-Year
Adaptive reimbursement era
Developments: Payment for many chronic interventions may update dynamically based on live outcome evidence.
Risks: Excess surveillance and data misuse could trigger public backlash.
Outlook: The long-run legacy is a reimbursement system that pays for measured health movement, not isolated services.
Planning prompts to verify
- Monitor additional TEMPO selections and whether they cover conditions beyond glucose and metabolic care.
- Track CMS public reporting of ACCESS risk-adjusted outcomes once enough patients enroll.
- Compare device-generated outcome claims with claims-based spending and adverse-event signals.